Preliminary study on transgender leukemia patients was exhibited at ALF 2019 as a research poster.
An article profiled this research was published to MD Edge: Hematology & Oncology:
NEWPORT BEACH, CALIF. – Researchers have shown they can identify transgender leukemia patients by detecting gender-karyotype mismatches, but some transgender patients may be overlooked with this method.
The researchers’ work also highlights how little we know about transgender patients with leukemia and other cancers.
Continue reading at MD Edge’s web site at https://www.mdedge.com/hematology-oncology/article/199253/aml/study-highlights-lack-data-transgender-leukemia-patients.
Alison Alpert, MD, of the Wilmot Cancer Institute at the University of Rochester Medical Center was interviewed during the conference by reporter Jennifer Smith and the interview was recorded by videographer Tyler Mundhenk. An edited video of the interview was posted at the web site with the article. Here is a video transcript:
“There’s almost no data about transgender people with cancer—in terms of prevalence or anything else. And because we don’t know which patients with cancer are transgender, we can’t begin to answer any of the other big questions for patients, such as: Are there health disparities among transgender patients with cancer and if so how can we address them? Is it safe to continue hormone therapy through treatment including allogeneic stem cell transplant? When is it possible if it all to do transition-related surgeries in the context of cancer care? But because we don’t even know who is transgender, we can’t begin to try to understand the answers to those questions and counsel patients.
“So what we did was identify a small subsegment of patients who are transgender who have leukemia. We mostly pointed out how little information we have. Oncologists don’t routinely collect identity information and this information doesn’t exist in cooperative group databases either. But going forward, what probably really needs to happen is that oncologists needs need to ask their patients whether they are transgender or not–and then ideally–consent forms for large cooperative groups like SWOG would include gender identity data and then we’d be able to answer some of our other questions and better counsel our patients.”